As­traZeneca sells off more as­sets from its is­land of mis­fit drugs in $1.6B Pfiz­er deal

As­traZeneca has com­plet­ed an­oth­er stage in its sys­tem­at­ic re­treat from the an­tibi­otics busi­ness, sell­ing a port­fo­lio of mar­ket­ed and ex­per­i­men­tal small mol­e­cule an­tibi­otics to an …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER